HLA-driven variability in human cytomegalovirus immune recognition: Epitope predictions from a kidney transplant Cohort
7 affiliations
- 1Facultad de Ciencias Biológicas, Universidad Nacional Mayor de San Marcos, Av. Carlos Germán Amezaga, Lima, Peru
- 2Pathogen Genetics Research Group (PATHO-GEN), Organization for Medical Innovation and Collaboration for Sciences (OMICS), Lima, Peru
- 3Immunology and Cancer Research Group (IMMUCA), Organization for Medical Innovation and Collaboration for Sciences (OMICS), Lima, Peru
- 4Facultad de Medicina Humana, Universidad Católica de Santa María, Arequipa, Peru
- 5Área de Histocompatibilidad y Biología Molecular, Hospital Nacional Carlos Alberto Seguin Escobedo, Red Asistencial Arequipa, Seguro Social de Salud (EsSalud), Arequipa, Peru
- 6Facultad de Medicina, Universidad Nacional Mayor de San Marcos, Lima, Peru
- 7Escuela de Postgrado, Universidad Católica de Santa María, Arequipa, Peru
Abstract
Background: Human cytomegalovirus (HCMV) infection causes life-threatening complications in transplant recipients. Despite a seroprevalence exceeding 90% in Peru, the influence of HLA diversity on HCMV immune recognition remains unexplored in the South American region. We aimed to characterize the HLA allele distribution in a Peruvian cohort and evaluate its impact on the predicted HCMV antigen-presentation landscape. Methods: HLA genotyping (loci A, B, C, DRB1, DQA1, DQB1) was performed in 562 kidney transplant candidates and related donors. Common allele groups (AF5%) were assigned 4-digit resolution proxies based on local prevalence. Linear T-cell epitopes from the immunodominant antigens 65 kDa phosphoprotein (pp65), Immediate early protein 1 (IE1), and Envelope glycoprotein B (gB) were predicted using high-performance algorithms. Allelic capacity to strongly bind antigenic peptides was quantified using the Predicted Strong Binder Density (PSBD). Results: We identified 16 HLA-I and 10 HLA-II common allele groups; 92% of their 4-digit proxies are widely distributed in SAM, while C*15:12 emerged as a potentially endemic variant in Peru. Screening yielded 954 HLA-I candidate epitopes, including 169 that correspond to previously reported IEDB epitopes with potential for immunotherapy. PSBD analysis revealed distinct predicted antigen-presentation profiles across the common HLA variants identified. Conclusion: Our findings provide updated Peruvian HLA data and define regional HCMV antigen-presentation profiles based on predicted MHC-peptide binding affinity (PSBD). Further experimental validation of these high-confidence candidate epitopes and HLA-HCMV association studies will be necessary to determine their immunogenicity and potential utility for immune monitoring and future immunotherapeutic applications across South American populations.
Related
- Uneven TCR chain pairing constraints govern epitope recognition
- Correlation Between Health Literacy and Tacrolimus Variability in Solid Organ Transplant Recipients
- Decoding antibody-antigen recognition: the BL8 language and its application in calibrating deep learning predictions
- Modeling congenital cytomegalovirus infection in human inner ear organoids
- Human cytomegalovirus microRNAs target the Wnt signaling protein Dishevelled 3 to promote efficient reactivation in CD34+ hematopoietic progenitor cells
BibTeX
@article{rosado2026hladriven,
title = {{HLA-driven variability in human cytomegalovirus immune recognition: Epitope predictions from a kidney transplant Cohort}},
author = {Mirella Dara Moreno Rosado and Tatiana Chavez-Arias and Obert Marín-Sánchez and Ricardo J. Juarez Zevallos and Alexis Germán Murillo Carrasco and César A. Ortiz Rojas and Yuma Ita-Balta and Ruy Diego Chacón Villanueva},
journal = {PLOS One},
year = {2026},
month = oct,
doi = {10.1371/journal.pone.0360632},
url = {https://doi.org/10.1371/journal.pone.0360632},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - HLA-driven variability in human cytomegalovirus immune recognition: Epitope predictions from a kidney transplant Cohort
AU - Mirella Dara Moreno Rosado
AU - Tatiana Chavez-Arias
AU - Obert Marín-Sánchez
AU - Ricardo J. Juarez Zevallos
AU - Alexis Germán Murillo Carrasco
AU - César A. Ortiz Rojas
AU - Yuma Ita-Balta
AU - Ruy Diego Chacón Villanueva
PY - 2026
DA - 2026/10/15
JO - PLOS One
DO - 10.1371/journal.pone.0360632
UR - https://doi.org/10.1371/journal.pone.0360632
AB - Background: Human cytomegalovirus (HCMV) infection causes life-threatening complications in transplant recipients. Despite a seroprevalence exceeding 90% in Peru, the influence of HLA diversity on HCMV immune recognition remains unexplored in the South American region. We aimed to characterize the HLA allele distribution in a Peruvian cohort and evaluate its impact on the predicted HCMV antigen-presentation landscape. Methods: HLA genotyping (loci A, B, C, DRB1, DQA1, DQB1) was performed in 562 kidney transplant candidates and related donors. Common allele groups (AF5%) were assigned 4-digit resolution proxies based on local prevalence. Linear T-cell epitopes from the immunodominant antigens 65 kDa phosphoprotein (pp65), Immediate early protein 1 (IE1), and Envelope glycoprotein B (gB) were predicted using high-performance algorithms. Allelic capacity to strongly bind antigenic peptides was quantified using the Predicted Strong Binder Density (PSBD). Results: We identified 16 HLA-I and 10 HLA-II common allele groups; 92% of their 4-digit proxies are widely distributed in SAM, while C*15:12 emerged as a potentially endemic variant in Peru. Screening yielded 954 HLA-I candidate epitopes, including 169 that correspond to previously reported IEDB epitopes with potential for immunotherapy. PSBD analysis revealed distinct predicted antigen-presentation profiles across the common HLA variants identified. Conclusion: Our findings provide updated Peruvian HLA data and define regional HCMV antigen-presentation profiles based on predicted MHC-peptide binding affinity (PSBD). Further experimental validation of these high-confidence candidate epitopes and HLA-HCMV association studies will be necessary to determine their immunogenicity and potential utility for immune monitoring and future immunotherapeutic applications across South American populations.
SN - 1932-6203
ER -